METRONOMIC CHEMOTHERAPY: ROLE IN DEVELOPING COUNTRIES FOR HEAD AND NECK CANCER
Abstract
NAReferences
Sankaranarayanan R, Masuyer E, Swaminathan R, et al. Head and neck cancer: A global perspective on epidemiology and prognosis. Anticancer Res 1998;18:4779-86.
Agarwal AK, Sethi A, Sareen D, et al. Treatment delay in oral and oropharyngeal cancer in our population: The role of socio economic factors and health-seeking behaviour. Indian J Otolaryngol Head Neck Surg 2011;63:145-50.
Patel UA, Lynn-Macrae A, Rosen F, et al. Advanced stage of head and neck cancer at a tertiary-care county hospital. Laryngoscope 2006;116:1473-7.
Kumar S, Heller RF, Pandey U, et al. Delay in presentation of oral cancer: A multifactor analytical study. Natl Med J India 2001;14:13-7.
Chintamani, Tuteja A, Khandelwal R, et al. Patient and provider delays in breast cancer patients attending a tertiary care centre: A prospective study. JRSM Short Rep 2011;2:76.
Riaz MK, Bal S, Wise-Draper T. The impending financial healthcare burden and ethical dilemma of systemic therapy in metastatic cancer. J Surg Oncol 2016;114:323-8.
Joshi P, Nair S, Chaturvedi P, et al. OP140: Delay in seeking specialist medical care and advanced oral cavity cancer: Experience in a tertiary care centre, India. Oral Oncol 2013;49 Supplement 1:S58.
De Felice F, Musio D, Tombolini V. Head and neck cancer: Metronomic chemotherapy. BMC Cancer 2015;15:677.
Browder T, Butterfield CE, Kräling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-86.
Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000;105:R15-24.
Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007;56:641-8.
Patil VM, Noronha V, Joshi A, et al. A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck. Oral Oncol 2015;51:279‑86.
Noronha V, Joshi A, Marfatia S, et al. Health-related quality of life in patients with metastatic, relapsed, or inoperable squamous cell carcinoma of the head and neck in India. Support Care Cancer 2016;24:1595-602.
Patil VM, Noronh V, Joshi A, et al. Metronomic palliative chemotherapy in maxillary sinus tumor. South Asian J Cancer 2016;5:56-8.
Parikh PM, Hingmire SS, Deshmukh CD. Selected current data on metronomic therapy (and its promise) from India. South Asian J Cancer 2016;5:37-47.
Patil VM, Chakraborty S, Jithin TK, et al. An audit of the results of a triplet metronomic chemotherapy regimen incorporating a tyrosine kinase inhibitor in recurrent/metastatic head and neck cancers patients. South Asian J Cancer 2016;5:48-51.
Mateen A, Adil AR, Maken RN, et al. Metronomic chemotherapy in recurrent head and neck cancer. Clin Oncol 2015;33:e17007. Available from: http://www.meetinglibrary.asco.org/content/144149-156. [Last cited on 2017 Feb 26].
Pandey A, Desai A, Ostwal V, et al. Outcome of operable oral cavity cancer and impact of maintenance metronomic chemotherapy: A retrospective study from rural India. South Asian J Cancer 2016;5:52-5.
Lam P, Yuen AP, Ho CM, et al. Prospective randomized study of post-operative chemotherapy with levamisole and UFT for head and neck carcinoma. Eur J Surg Oncol 2001;27:750-3.
Fujii M, Ohno Y, Tokumaru Y, et al. Adjuvant chemotherapy with oral tegaful and uracil for maxillary sinus carcinoma.Oncology 1998;55:109-15.
Petry V, Gagliato DM, Leal AI, et al. Metronomic chemotherapy in the neoadjuvant setting: Results of two parallel feasibility trials (TraQme and TAME) in patients with HER2+ and HER2-locally advanced breast cancer. Braz J Med Biol Res 2015;48:479-85.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors retain copyright and grant the Journal of Cancer & Allied Specialties (JCAS) right-of-first publication. In addition, the work will be simultaneously licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license. This license allows others to share the work in whole or part (for non-commercial purpose), with an acknowledgement of the work’s authorship and initial publication in JCAS.
Furthermore, authors are free to enter into separate contractual arrangements for the non-exclusive distribution of the journal’s published version of the work, with an acknowledgement of its initial publication in this journal.
Authors are permitted and encouraged to share their work online or in medical or scientific conferences prior to or during submission process.
